What a 503A Compounding Pharmacy Is Allowed to Do

The legal basis

Section 503A of the Federal Food, Drug, and Cosmetic Act creates an exemption allowing a licensed pharmacist or physician to compound a drug for an identified individual patient against a valid prescription, without that product going through FDA approval.

The exemption exists for a practical reason: patients sometimes need a formulation that is not commercially available — a different strength, a liquid instead of a tablet, a preparation free of an allergen.

What the exemption costs

Compounded preparations are not FDA-approved. They have not been evaluated for safety or efficacy, and their manufacturing has not been reviewed premarket. That is not a loophole being exploited; it is the explicit trade-off the statute makes.

Oversight comes primarily from state boards of pharmacy, with FDA retaining authority over adulteration and misbranding. It is a genuinely different regulatory posture from an approved drug product.

503A versus 503B

503A pharmacies compound patient-specific preparations against individual prescriptions, in limited quantities, without advance orders. 503B outsourcing facilities may compound in larger volumes without patient-specific prescriptions, and in exchange register with FDA and comply with drug cGMP.

Anyone producing at scale for office stock should be a 503B. A facility doing 503B-scale work under a 503A licence is outside the category it claims.

Real constraints on what can be compounded

Compounding is restricted where a product is essentially a copy of a commercially available approved drug, and where a substance appears on FDA's demonstrably difficult to compound list. Bulk substances used must generally appear on approved lists or be components of approved drugs.

The rules also tighten and loosen around drug shortages, which is why permissibility in this space has shifted over recent years and why yesterday's answer is not always today's.

What this means for a patient

A legitimate compounded preparation involves a genuine prescriber-patient relationship, a licensed pharmacy you can verify with the state board, clear labelling with lot and beyond-use date, and a pharmacy willing to tell you where its bulk substance came from.

What it is not is a cheaper version of an approved drug with identical assurances. Understanding that trade-off is the point of knowing the category exists.